Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 3/20 | 0.31 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.30 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.30 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235890 | 1.00 | SYK (0.31) | SYKKDM4ENPC1RAB9APDE4D | |
| SCHEMBL22235382 | 0.90 | TP53 (0.34) | KDM4EPDE4D | |
| SCHEMBL22235380 | 0.90 | TP53 (0.34) | KDM4EPDE4D | |
| SCHEMBL29728922 | 0.90 | TP53 (0.34) | KDM4EPDE4D | |
| SCHEMBL22235509 | 0.90 | TP53 (0.34) | KDM4EPDE4D | |
| SCHEMBL22235228 | 0.84 | PDE4D (0.34) | SYKPDE4DTNKSTNKS2 | |
| SCHEMBL22235977 | 0.84 | PDE4D (0.34) | SYKPDE4DTNKSTNKS2 | |
| SCHEMBL29728932 | 0.84 | PDE4D (0.34) | SYKPDE4DTNKSTNKS2 | |
| SCHEMBL22235222 | 0.84 | PDE4D (0.34) | SYKPDE4DTNKSTNKS2 | |
| SCHEMBL22235214 | 0.83 | KDM4E (0.32) | KDM4ENPC1RAB9APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-04-28 | — | — | US | disclosed |
| CN-113825756-A | Substituted polycyclic carboxylic acids, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911653-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150366-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, HDGF | SYK 3688/4885KDM4E 1195/4885NPC1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.